Media Coverage

Advanced Search
  • 02162024
    Dermatology Times

    Quest Diagnostics on Tuesday announced a new tool available to dermatologists for making treatment decisions for patients with melanoma. The gene expression test, MelaNodal Predict, is based on technology developed by the oncology biotechnology company SkylineDx and researchers at Mayo Clinic.

  • 02132024
    The Daytona Beach News-Journal

    Years of exposure to nonstick cookware, fast-food packaging, fire-fighting gear and water-resistant household products have resulted in increased levels of PFAS, also known as "forever chemicals," in practically every American's bloodstream. Quest Diagnostics announced Monday the first "consumer-initiated, physician-ordered blood-draw test for PFAS chemicals." The test, which you order online, will be available from most of Quest's approximately 2,100 diagnostic centers in the country and will include (if desired) a separate telephone consultation with a licensed physician to go over the results and ways to reduce the exposure risk.

  • 02062024

    Suhash Harwani, Ph.D, Senior Director of Science & Technology for Employer Solutions at Quest Diagnostics, shares drug positivity and testing options that employers should know about.

  • 01312024
    Becker's Hospital Review

    On Jan. 31, Fortune released its World's Most Admired Companies list, which included healthcare companies. The list, a partnership between Fortune and global management consulting firm Korn Ferry, follows an examination of about 1,500 candidates: the 1,000 largest U.S. companies ranked by revenue, along with non-U.S. companies in Fortune's Global 500 database that have revenues of $10 billion or more.

  • 01172024
    Fierce Biotech

    Just as users around the world are surely strapping on new Fitbits with an aim of tackling health-focused New Year’s resolutions, so too is Fitbit itself kicking off 2024 with its sights set on a new goal. The Google-owned fitness tracker maker is teaming up with Quest Diagnostics, according to a Wednesday release, to study how the combination of the two companies’ products could potentially help improve metabolic health, which is linked to conditions like diabetes, heart disease and stroke.

  • 01092024
    Lab Pulse

    Quest Diagnostics has acquired select assets of outreach laboratory services in Pennsylvania and Ohio from Steward Health Care System, a large, private, and fully-integrated for-profit system based in Dallas. In addition, subject to transfer of the laboratory license, Quest has also acquired certain assets from the laboratory business serving Hawthorn Medical Associates in Dartmouth, MA.

  • 01082024

    Haystack Oncology said on Monday that it has struck a deal to investigate the use of its minimal residual disease (MRD) testing technology in non-small cell lung cancer (NSCLC) in collaboration with research organization Alliance Foundation Trials (AFT).

  • 12272023
    CAP Today

    Quest Diagnostics and Scipher Medicine announced a collaboration designed to expand patient access to diagnostic services for rheumatoid arthritis. Under a multiyear collaboration, Quest will provide RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular signature response classifier aimed at predicting a patient’s response to TNF inhibitor therapy.

  • 12192023
    Clinical Lab Products

    Quest Diagnostics unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.

  • 12172023
    Health IT Answers

    On this episode I talked to Michael Racke, MD Medical Director of Neurology at Quest Diagnostics. Michael discusses promising advancements in our understanding and treatment of Alzheimer’s disease. He explains how imaging and biomarkers have allowed earlier and more accurate diagnosis, moving from just a clinical picture to actually visualizing amyloid plaques and tau tangles in the brain.